非布司他用于慢性肾脏病无症状高尿酸血症的治疗 - Suppr | 超能文献

Febuxostat for Asymptomatic Hyperuricemia in CKD.

作者信息

Mome Ruth, Bakinde Nicolas

机构信息

Morehouse School of Medicine, Atlanta, Georgia.

出版信息

Am J Kidney Dis. 2016 Jun;67(6):989. doi: 10.1053/j.ajkd.2015.09.035.

DOI:10.1053/j.ajkd.2015.09.035

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Febuxostat for Asymptomatic Hyperuricemia in CKD.非布司他用于慢性肾脏病无症状高尿酸血症的治疗

Am J Kidney Dis. 2016 Jun;67(6):989. doi: 10.1053/j.ajkd.2015.09.035.

2

In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.回复《非布司他用于慢性肾脏病无症状高尿酸血症》及《非布司他对慢性肾脏病无症状高尿酸血症患者的肾脏保护作用》

Am J Kidney Dis. 2016 Jun;67(6):990-1. doi: 10.1053/j.ajkd.2016.04.001.

3

Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.非布司他对无症状高尿酸血症慢性肾脏病患者的肾脏保护作用

Am J Kidney Dis. 2016 Jun;67(6):989-90. doi: 10.1053/j.ajkd.2015.09.034.

4

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.非布司他：一种选择性黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂，用于治疗成人痛风患者的高尿酸血症。

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033.

5

Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.安慰剂对照、双盲、剂量反应研究日本高尿酸血症（包括痛风患者）患者中黄嘌呤氧化酶抑制剂非嘌呤选择性抑制剂 febuxostat（TMX-67）：第 2 期后期临床研究。

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S35-43. doi: 10.1097/RHU.0b013e31821d351d.

6

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.一种别嘌醇对照、随机、双盲、双模拟、平行分组、比较研究，评估黄嘌呤氧化酶非嘌呤选择性抑制剂非布司他（TMX-67）在包括痛风患者在内的高尿酸血症患者中的疗效：3 期临床研究。

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

7

Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.安慰剂对照、双盲研究非嘌呤选择性黄嘌呤氧化酶抑制剂 Febuxostat（TMX-67）在包括痛风患者在内的高尿酸血症患者中的应用：III 期临床研究。

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S19-26. doi: 10.1097/RHU.0b013e31821d36de.

8

An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.一项别嘌醇对照、多中心、随机、开放标签、平行分组、比较研究，评估黄嘌呤氧化酶非嘌呤选择性抑制剂非布司他（TMX-67）在日本高尿酸血症患者（包括痛风患者）中的疗效：Ⅱ期探索性临床研究。

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44-9. doi: 10.1097/RHU.0b013e31821d352f.

9

Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.非布司他用于痛风和严重慢性肾脏病患者：合适的剂量是多少？对萨格等人文章的评论

Arthritis Rheumatol. 2016 Oct;68(10):2563-4. doi: 10.1002/art.39769.

10

Febuxostat--treatment for hyperuricemia and gout?非布司他——用于治疗高尿酸血症和痛风？

N Engl J Med. 2005 Dec 8;353(23):2505-7. doi: 10.1056/NEJMe058247.

引用本文的文献

1

Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study.非布司他不同剂量对痛风患者尿酸、血清及膝关节腔炎症因子、内皮素-1和氧化应激的影响——一项对比研究

Afr Health Sci. 2024 Dec;24(4):313-324. doi: 10.4314/ahs.v24i4.40.